Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin

BACKGROUND: Amrubicin chemotherapy is a treatment option for patients with non‐small cell lung cancer (NSCLC) after third‐line treatment in Japan. Although topoisomerase‐II (Topo‐II), a target of amrubicin, has been reported to be a prognostic or predictive marker for chemosensitivity and clinical o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakurai, Reiko, Kaira, Kyoichi, Miura, Yosuke, Sunaga, Noriaki, Saito, Ryusei, Oyama, Tetsunari, Hisada, Takeshi, Yamada, Masanobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997014/
https://www.ncbi.nlm.nih.gov/pubmed/31901017
http://dx.doi.org/10.1111/1759-7714.13289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997014/
https://www.ncbi.nlm.nih.gov/pubmed/31901017
http://dx.doi.org/10.1111/1759-7714.13289

Ejemplares similares